Good morning and thank you for standing by. Welcome to ImmunoPrecise Antibodies first quarter fiscal 2023 earnings conference call. Also on the call with us today are Jennifer Bath, Chief Executive Officer, Brad McConn, Chief Financial Officer, Ilse Roodink, Chief Scientific Officer, and Barry Duplantis, Vice President of Client Relations. Before we get started, remember some statements we make today may be considered forward-looking statements for the purpose of applicable United States and Canadian securities laws. IPA cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. IPA undertakes no obligation to update these forward-looking statements except as required by law. On today's conference call, non-GAAP financial measures may be used to help investors understand IPA's business performance. We refer current and potential investors to our forward-looking information section of its management's discussion and analysis issued today at www.sedar.com and on EDGAR at www.sec.gov. Following our prepared remarks, we'll answer analyst and investor-submitted questions. With that, I'll now turn the call over to Dr. Bath. Great. Thank you, Julianne. Good morning, everyone, and thank you for joining us today. We are pleased to offer Q1 updates on the heels of our year-end results and as we enter this fiscal year with aggressive strategic aims, many of which we'll share with you today. We remain highly confident in our ability to grow revenues through new and existing clients, novel high revenue values, high-value revenue streams, and importantly, the commercialization of disruptive AI-driven in silico technologies offered through our newest subsidiary, BioStrand. Additionally, four of our potential best-in-class and first-in-class therapies from our internal pipeline are now positioned for active licensing with the aim of commercialization this fiscal year. Lastly, we simultaneously prepare the regulatory submission of IPA for anti-SARS-CoV-2 antibody therapeutics, which have sailed through preclinical IND enabling studies and remain the only first generation therapy to retain efficacy against all tested variants of concern, including the most recently screened BA.2.75, with more details on that program to come on this call from Dr. Roodink. IPA employees and their directors are particularly excited about the opportunities emerging from our most recent acquisition, BioStrand. It's been exactly five months today since the closing of this transaction, and both teams have been working tirelessly at delineating what the initial outcomes of these two companies coming together could be. If what has come to fruition up to this point is indicative of the future, IPA is about to engage in a disruptive and game-changing path forward. BioStrand proposes a truly transversal and universal solution based on technologies that apply to every studied species, any sequencing format for data generation, and any application domain. As many of you know, many years ago, BioStrand made a pivotal discovery by identifying underlying universal fingerprints at the core of the biosphere's amino acid and nucleotide space. Those fingerprints, termed HYFTs after the inventor's name, Dirk Jan Haft, unlock meaning and insight through multiple omic dimensions analyzed concurrently. Impossible with other technologies, the task of computing in parallel is now achieved by this remarkable and elegantly coded and indexed platform that renders near instantaneous results. We believe this will revolutionize the antibody drug discovery and development market as it results in knowledge and insights that dramatically speed up parallel hypothesis generation, target identification, antibody discovery, antibody engineering, and druggability profiling. Months, if not years, may be saved with razor-sharp precision in the results generated. Therapeutic discovery is no longer just the purview of biologists. It's now interdisciplinary and heavily influenced by the fields of computational modeling and data science. Actionable data is the first prerequisite for making progress in the world of personalized medicine, of which the global market science is expected to reach $5.7 trillion by 2030, and to expand at a CAGR of 11.6% from 2020 to 2030. The industry is being driven primarily by increasing prevalence of malignancies and genetic illnesses. Additionally, a massive influx of expenditures in R&D and healthcare IT is supporting industry expansion of these patient-tailored therapies. In order to create specialized treatment plans, fine-grained knowledge on disease mechanisms and stages is needed in combination with the identification and analysis of patient-specific biomarkers, especially in cancer and unusual genetic illnesses. Better outcomes are expected with more precise and personalized approaches to treatment. Now that said, the sheer volume of available data and their multilayered nature, such as omics data or textual data and clinical data, have historically restricted data integration. In addition, these data are all stored in silos and in different formats, which further complicates valuable integration. As a result, readability has been quasi-null, and efforts are deployed in computer power instead of understanding what data actually is relevant to discovery of safe and effective therapies and personalized medicine. LENSai from BioStrand data management successfully solves this problem and provides a hyper-scalable solution, integrating multiple data layers at once. LENSai proprietary technology turns unstructured big data into structured big data and allows for instantaneous, instantaneously actionable and computed data. All data is secure and an easy-to-use access system is in build-out. This will be the foundation for a highly sophisticated data management solution to help partners maximize large internal data lakes, which may have been accumulating for decades without being taken full advantage of. The depth and richness of these libraries remains to be explored and analyzed in a feedback loop process in order to continuously enrich our partners program and turn data storage, which is a sunk cost for them, into an asset. The unique offering of LENSai analysis platform is to rapidly bridge the gap between sequence analysis, 3D protein structure information, and the knowledge hidden in the different text documents, all using proprietary HYFTs. We are pleased to announce that building further on the cornerstone of LENSai technology, similar to our original HYFT fingerprints, we have now generated structural HYFT fingerprints, which are fully built, also indexed into the software and are now operational. This opens up a whole gateway to even more complex and integrated analysis for what we believe will revolutionize the fields of antibody humanization, epitope prediction, biosimilar antibody generation, and epitope-paratope binding predictions. As may be becoming clear within the context of what we are sharing, one of the several powerful cornerstones of IPA is now connecting and integrating data science and bioscience. We believe this will enable us to tackle in the near future discovery challenges not previously possible through in silico means. These disruptive capabilities are then supported by our exceptionally broad downstream antibody development capabilities to provide high quality products with exceptional speed in the process of taking a therapy from concept to clinic. We are very pleased to announce on this call that as of today, we've made tremendous progress on multiple in silico fronts. First, we have implemented powerful structural prediction capabilities. After a full implementation of DeepMind's AlphaFold on our servers, we indexed our recently completed structural HIFT and then applied structural search capabilities to our workflow. This now enables us to navigate seamlessly the structural world of biology and to generate more specific structural predictions and insights, all based on our proprietary HIFT syntax and structural HIFT indexes. Recalling that in biology, structure equates to function, and that function is at the heart of every biological activity. This effectively means that we are able to search related functions coded in HIFT. Second, we have expanded our database extensively with antibody libraries, structural libraries, scientific literature, and the integration of Talem's proprietary data lake derived from multi-species genome reference sequencing, structural crystallography and functional metadata, all to improve and enrich analytical capabilities for both IPA and Talem. Third, and lastly, we've also evolved LENSai into a self-adaptive feedback loop platform, where HIFTs are continuously enriched with structural and functional metadata, accelerating time for discovery and supporting our world-class function first B cell platform. Building on these recent advances, we've spent the past quarter generating multiple exciting case studies with in silico validation, which are pending wet lab validations with final results aimed at release this quarter. Based on these initial in silico findings, we have garnered interest from partners on multiple high-value programs using our newest in silico technologies. This confirms that the industry is shifting toward in silico development more than ever, and that the appetite for emerging and disruptive technologies is high. High-value targets are increasingly complex. Together with an ever-growing interest in discovering new targets, the industry needs new tools to alleviate the difficulty level to achieve success. LENSai is unequivocally positioning itself as a powerful and unparalleled, fully integrated in silico and wet lab engine. While we won't be sharing any of our in silico validated case studies under in vitro review until later this quarter, we are happy to share one of our case studies that we produced since last April. This one with the aim of analyzing a blockbuster monoclonal antibody that had been sponsored by a top ten pharma that was deemed a commercial success, but for which adverse events emerged and were occasionally fatal. Our objective was to determine why the antibody under review had elicited undesirable adverse events in patients, as well as to determine if our LENSai could have predicted these complications, possibly even preventing fatalities. For anonymity, as we are preparing to share the final result with the sponsoring pharmaceutical company, we'll simply call the antibody of interest Antibody X. As an example of one of our earlier case studies, Antibody X is a commercial stage anti-cytokine antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. By using HYFT transcribed omics sequence data and a binding prediction algorithm, we identified what we believe to be a common binding site between Antibody X and the fungus Aspergillus. We then applied our bottom-up NLP approach for scientific literature analysis to extract multiple biomedical reports, which pointed to a link between Antibody X treatments and allergic bronchopulmonary aspergillosis, an exaggerated response of the immune system to the fungus Aspergillus. Our LENSai software indicated the following. Antibody X was capable of binding to Aspergillus and was causing severe allergic reactions in some patients who had been treated with the antibody. This novel interaction could have been predicted using BioStrand's holistic multi-species approach, which would have helped prevent the adverse events by allowing the sponsor to preclude patients with previous Aspergillus infection from both the clinical trials and also from post-trial treatments. This case study represents only a small portion of the clinically relevant breakthroughs that we believe LENSai is capable of solving. The in silico case studies currently undergoing wet lab validation are focused on demonstrating the ability of HYFTs to rapidly revolutionize the fields of antibody humanization, transgenic animal usage, biosimilar discovery and development, in silico identification of antibody functions, and much more. As a result, we believe our LENSai software, combined with our broad wet lab capabilities, will ultimately disrupt multiple industries in the relatively near future. With that, I'll go ahead and turn things over to Dr. Barry Duplantis, Vice President of Client Relations. Thank you, Jennifer. We will now start with the performance review of our CRO business. When comparing this quarter to the same period last year, the company's project revenue has been quite consistent. However, we have noted several highlights that indicate growth as we look to the future. Firstly, discovery-based sales orders, which are signed commitments of future work, are up at our Canadian site by 67.5% and 18% globally. While this is a very promising metric, we do like to remind those listening that based on program timelines, IPA will be recognizing this revenue over a period of 0-10 months. Secondly, the number of multi-phase discovery project starts, including our B cell Select, phage display, and hybridoma platforms, are up 125% at our Canadian site and 100% globally. The primary driver for both sales orders and project starts can be attributed to an increased demand for IPA's rabbit B cell platform. IPA began a sales and marketing push in the beginning of Q4 last year, targeting the therapeutic companion market. Therapeutic companion antibodies are critical and necessary reagents required to bring a therapeutic drug to market. The combination of IPA's function-first B cell Select workflow and the untapped potential of the rabbit's immune system produces highly selective, high-affinity antibodies that provide our clients with a best-in-class solution to complete a critical piece of the therapeutic equation. Thirdly, IPA has just completed the onboarding of another major pharmaceutical company, meaning that IPA now has had a contract service-based relationship with 80% of the globe's top 20 pharmaceutical companies. Finally, IPA has begun to see an increased impact from hedge fund-backed virtual biotherapeutic companies that lack or are very limited in wet lab facilities and capabilities and are often headed by researchers that have had previous experience with IPA's team and services while serving in past position at other IPA client companies. An example of this impact is represented by the fact that in this past quarter, two of IPA's top five revenue-generating clients operate with less than 10 employees. This contrasts with zero of our top five clients from Q1 a year ago. While IPA is always developing and expanding relationships with major pharmaceutical companies, we expect to see and will actively pursue an increase in partnerships with small, fully virtual companies. These companies can be more agile, they have substantially lower operating costs, often have significant budgets, and seek to leverage the expertise and platforms of CROs to succeed and meet their objectives within the constraints of the current global financial environment. With that final update, I'm going to turn things over to Ilse. Thank you, Barry. We are excited to turn our attention to Talem Therapeutics, where we will be discussing our recent scientific developments and current outlicensing efforts with regard to five key Talem assets. Our PolyTope program, also known as TATX-03, TrkB, or TATX-112, TATX-24, our companion arm for bi or multi-specifics, and TATX-114. For PolyTope, our TATX-03, it is our Talem's first generation for antibody combination therapy against SARS-CoV-2. Unlike commercially available therapies, PolyTope remains effective against every variant and sub-variant of concern. This confirmed efficacy most recently includes the currently circulating BA.2.75 variant, which was shown to be neutralized by PolyTope using in vitro pseudovirus screenings. Because of PolyTope's performance in the neutralization assays and in vivo and in vitro preclinical safety and quality assessments, Talem has received strongly positive regulatory feedback from the EMA and is now finalizing clinical trial agreements and pushing hard to move PolyTope into the clinic. The following slide summarizes our path towards this milestone. Unfortunately, the clinical material manufacturing facility recently faced a COVID-associated lockdown, extending the completion of the manufacturing documentation for a clinical trial application by an estimated two months. Based on this revised timeline, submission of the clinical trial application to the regulatory authority is scheduled for Q4 of this year, with the first in-human trial expected to start early calendar year 2023. In addition, as previously announced, we are collaborating with Elektrofi to create subcutaneous version of our TATX-03 antibody combination therapy. We screened several formulations to identify compositions that reach a concentration approximately 4x-10 x higher than standard antibody formulations to facilitate subcutaneous administration of our PolyTope product. The prioritized formulation will be used for evaluation in IND enabling studies. On the business front, Talem has engaged and issued a contract with a well-respected key opinion leader with expertise in the co-commercialization of therapeutic antibodies. With this new relationship, Talem will emphasize the value proposition associated with commercialization of an infectious disease asset such as PolyTope. These programs are known to have very favorable earning potential in terms of the clinical cost to asset revenue ratio, a factor that's often overlooked due to the lack of infectious disease clinical trial expertise in the industry. Building on the already attractive market position, Talem has secured an extremely advantageous manufacturing deal that should alleviate any concerns associated with the manufacture of a four-antibody combination therapeutic. Finally, while the general public may perceive that the pandemic has ended, continuing global infections and market intelligence strongly point to the need for a more sustainable and broadly efficacious therapy. Next, we turn our attention to TATX-24, Talem's companion arm for bi or multi-specifics. Currently, Talem has identified a panel of antibodies that target a specific subset of highly desirable epitopes, while also showing varying levels of functional activation. This combination has produced assets that perform like, or potentially better than, a commercially available benchmark. Talem has leveraged these lead TATX-24 antibodies to create functional bispecific for its internal programs, including TrkB. This asset will be made available for out-licensing once the in vitro characterization data package is completed. The third asset of discussion is TATX-112. TATX-112 is a panel of antibodies directed towards TrkB, a cell surface receptor that is expressed on a wide range of solid tumors. In this program, we have identified candidates for use in a bispecific modality and in concert with antibody drug conjugates. In fact, Talem has combined TATX-112 and TATX-24 lead candidates into a bispecific format to create a proven T-cell engager that's able to recruit and activate T-cell. The cell-killing effects of this molecule are currently under investigation in ex vivo functional assays. Although the bispecific assets from this program have already been made available for out-licensing, we feel that this asset being potentially first and best in class, the addition of in vivo data would create a more complete data package to attract more favorable offers. To quickly wrap up the Talem pipeline developments, I will briefly touch on TATX-114 and TATX-22. The TATX-114 asset is being positioned as best in class. This marketing stance is based on binding characteristic comparisons to a commercial clinical benchmark. For TATX-22, we have previously reported potential partnerships involving this program. Based on the scientific discussions regarding the mechanism of action required for the partner's indication, the collaboration has evolved to include the application of BioStrand's LENSai. We are very excited about the directions of these conversations for both the perspective of a Talem out-licensing event as an opportunity to showcase the potential of LENSai. With this, I would like to turn the call over to Jennifer to discuss updates on our progress for the expanded facilities. Thank you, Ilse. Starting with the Netherlands, our team in Utrecht is preparing for their move to the recently completed accelerator building. The laboratory and IT infrastructure are ready, and the new equipment is being received and installed to support the planned increase in capacity for automated, high throughput, small and large scale recombinant protein production. The team is currently planning and scheduling test runs leading up to the official move-in date of mid-October. As previously announced, staff in Oss are also preparing a move to a new facility, which is currently under construction. We're fine-tuning the fit out to make sure it is in line with our expected growth and intended extension of services. Also, as recently announced, the expansion of our in-house vivarium located in Victoria, British Columbia, was completed during this first quarter, and the facility is now fully in use with a new procedure room and higher animal capacity to support the growing demand for IPA's antibody discovery programs. The team now continues its planning for the addition of new in vivo services, beginning with the PK and maximum tolerability dose preclinical studies, which are only now possible with these facility enhancements. With this, I would like to turn the call over to Brad to discuss the quarter's financial results in more detail. Thank you, Jennifer, and good morning, everyone. I'll provide an overview of our financial results for the first quarter before touching on our financial position as of the end of the period. As a reminder, all numbers I reference are in Canadian dollars unless otherwise noted. IPA recorded total revenue of CAD 4.7 million during the first quarter, a 2.2% increase from CAD 4.6 million during the first quarter of fiscal 2022. On a local level, we recorded revenue growth at all three operating sites year-over-year, with our strongest growth arising from our manufacturing site in Utrecht. One item I do want to highlight, we generate approximately 2/3 of our revenue at our sites in the Netherlands, which has caused our revenue on a consolidated basis to be negatively impacted by the weakening of the euro as results are translated into Canadian dollars. The negative impact of revenue during the first quarter was approximately CAD 300,000 as compared to the first quarter of fiscal 2022. Gross profit for the quarter totaled CAD 2.5 million, a decrease of 1.1% compared to the same period last year. Gross profit margin of 53% is likewise a slight decrease from 55% in fiscal 2022. The increased cost of sales is primarily attributable to higher cost for lab supplies and a project mix during the quarter requiring more work to be outsourced to third-party contractors. Operating expenses during the first quarter totaled $12.6 million, an increase of $6.6 million compared to the same period in fiscal 2022. Research and development expense was the primary driver of the rise in costs and totaled $5.8 million during the quarter. IPA continues to strategically invest in the PolyTope antibody combination therapy and incurred $5.2 million in cost during the quarter for GMP manufacturing of the therapy in quantities sufficient for phase I and phase IIA clinical trials. Salaries and benefits increased $700,000 compared to the first quarter of fiscal 2022 due to the addition of strategic leadership roles, routine pay increases, and additional staff added from the BioStrand acquisition. Amortization and depreciation increased $600,000, primarily the result of additional amortization of intangible assets arising from the BioStrand acquisition. Consulting fees increased $400,000 year-over-year due to services related to the BioStrand acquisition, and management fees totaled $200,000 as compared to nil during the first quarter of fiscal 2022 due to contracted general managers at the BioStrand site. Other income totaled $300,000 during the first quarter of fiscal 2023 compared to $400,000 during the same period last year. The largest variance of note is a decrease in unrealized foreign exchange gain of $400,000 compared to the first quarter of fiscal 2022. IPA recorded $300,000 in grant income compared to nil during the first quarter of fiscal 2022, as we received the first disbursement of funds from VLAIO, the research fund of the Flemish Regional government in Belgium. IPA recorded a net loss of $9.4 million during the first quarter of fiscal 2023, compared to a net loss of $3.2 million during the same period last year. As previously highlighted, the major drivers of the increase in net loss include increased investment in R&D, increased salaries and benefits, increased amortization and depreciation, and increased consulting fees. Moving on to the balance sheet. IPA held cash of $19.2 million as of July 31, 2022, compared to $30 million as of April 30, 2022. As previously noted, cash expenditures increased during the quarter as we made strategic investments in the PolyTope antibody combination therapy. In total, research and development expenses represented nearly 55% of our spend during the quarter. Additionally, our accounts payable balance decreased by $2.4 million as we paid expenses accrued in the prior year. Our expectation is for cash burn to slow over the next three quarters as expenditures on the PolyTope progressively decrease throughout the year. As we noted in previous quarters, IPA has put in place an at-the-market equity offering facility, which entitles us at our discretion and from time to time during the term of the ATM agreement to sell through our agent, H.C. Wainwright & Co., common shares having an aggregate gross sales price of up to $50 million. As of today, all $50 million of IPA stock remained available for sale under the ATM facility. With that, I will turn the call back over to Julianne and Jennifer for Q&A. Thanks, Brad. Before Jennifer adds any closing remarks, I would like to read some of the questions we received from analysts and investors. The first two questions are from Robert Wasserman from the Benchmark Company. The BioStrand group recently was awarded a grant in Belgium for HYFT-based methodology. Can you explain what the grant covers and why this technology is important? It appears that Ms. Bath's line has disconnected. We're just in the process of reconnecting her. Please stand by. Jennifer, you are reconnected. Would you like me to repeat the question for you? Sure. Hello. Yes. I was dropped from the line. Yep, if you have questions, so shoot away. Certainly. Our first two questions are from Robert Wasserman from The Benchmark Company, and the first question states, "The BioStrand Group recently was awarded a grant in Belgium for the HYFT-based methodology. Can you explain what the grant covers and why this technology is important? Yes, sure. Thank you. Thank you, Robert, for your question. That is correct. BioStrand recently received a EUR 460,000 grant from VLAIO, as referenced by Brad. This is from the Flanders Innovation & Entrepreneurship, which is a research fund of the Flemish regional government in Belgium. This grant is actually related to a number of the things that we shared about BioStrand's updates earlier today about the structural HYFTs and the indexing of those structural HYFTs to enable us to search with structure and ultimately function on our software. The grant basically builds on BioStrand's technology, which connects sequence information and structural information. As mentioned previously in biology, the structure tends to be more conserved than a sequence is, and it's very difficult typically to filter out sequences that have similar structures but have low sequence similarity. As the structure is actually very closely related to the function or to the activity of a molecule, you can imagine that detecting structure similarities accurately within a big data context is very relevant and momentous task in drug discovery. A key advantage and uniqueness of the BioStrand blended approach is the detection of protein sequences with similar structures and of course then functions, but without high sequence similarity. In other words, on most platforms, those would never be identified. A primary application for this approach is advanced structural search capabilities and structural predictions with a particular focus at first on antibodies as well as G protein-coupled receptors, better known as GPCRs. This will be extended to cover protein-protein interaction predictions at a later stage. We will be able to expand our services portfolio with HIAP-based structural and functional modeling functionalities. By linking HIAP with the 3D structure and function of proteins and expanding our platform capabilities for AI discovery, we support an even wider array of applications, including assay development, biomarker discovery, and computer-aided drug design. Thank you. Our second question from Robert Wasserman is, "Will IPA be presenting or exhibiting at any of the upcoming fall industry conferences, such as Boston Bio Week? If so, what will be the focus? Yep. We're actually really excited about this fall because we have all of these exciting case studies and new, AI-driven capabilities to share. IPA and also Talem have very busy schedules and are presenting and/or exhibiting at almost every one of these conferences. More specifically through November, the IPA sales team is planning to attend five conferences where we anticipate our focus not only to be at our advanced wet capabilities, wet lab capabilities of course, but a major emphasis on the new opportunities through BioStrand as we seek to present confirmatory studies demonstrating unprecedented in silico capabilities and offerings. We will be offering access to these technologies through alternative revenue formats that combine fee for service with downstream revenue tails. Thus far, as indicated previously, the couple of early adopters that we have proposed advanced technology access to under these revenue formats have been agreeable and enthusiastic. Of these conferences for the CRO group, three are in the U.S. and two are in Western Europe. As mentioned, our Talem team is also intending to attend and present and/or exhibit at seven different conferences through November as well. They will be dividing their efforts between partnering meetings with in-licensing decision makers, as well as presenting on IPA's capabilities as a leverage for Talem collaboration, with a core focus also on our in silico capabilities through the use of recently developed case studies. The Talem-focused conferences are very fairly even split between North America and Europe, and also include some specialty conferences such as the AACR or American Association for Cancer Research, a special conference on tumor immunology and immunotherapy. These next two questions are from Sepehr Manochehry from Eight Capital. Are there any additional end markets that you need to be close to? Have there been opportunities, customers you've had to turn down in the past? The answer would be yes and yes, and I'll start by saying, you know, the first end market that comes to mind, and I'll share, has been one that we have had to turn clients down on because we simply don't offer those capabilities. The primary end market we believe we should be closer to is that of clinical manufacturing, which is obviously closer to a clinical trial and the actual patient. After the discovery and development of a client's protein or antibody of interest at IPA, we often develop tailored manufacturing SOPs and can conduct research-grade manufacturing with customizable quality control for each product. However, when the client program requires a GLP product, for instance, like an IND submission data or GMP validated product for clinical trials or for commercialization, the client needs to move to a GMP validated third-party CDMO. On occasion, IPA can currently recommend the third party or even tech transfer the protocols for optimized expressions. However, with an extremely high client retention rate of around 95%, IPA is acutely aware of the fact that it is beneficial for both the client and IPA to complete the final workflow under one roof and with the consistency of materials, reagents, equipment, and staff from research grade all the way through clinical manufacturing. IPA is currently exploring options in this market, and last quarter we were awarded a grant in the Netherlands to support a significant portion of a GMP build-out. We're currently investigating additional opportunities for funding of a potential GMP facility in the Netherlands to leverage this initial funding. Our second question from Sepehr is, can you detail the capacity expansion plans at your facilities and the anticipated impact on financial performance? Sure. I'll take that one. In the near term, as Jennifer highlighted, our site in Utrecht will be completing the move to their new facility in mid-October, which will provide approximately double the lab space compared to their current location. This will help alleviate the capacity constraints that we currently have at our Utrecht site. While there will be a little bit of a ramp-up period, we expect to see increased production begin to reflect in our financial performance beginning in Q4 of this fiscal year. We've also announced plans for our Oss location to move to a new facility in the second half of calendar year 2023, in this case, increasing lab capacity by approximately 30%. As Jennifer just detailed in the previous question, additionally, in the Netherlands, we continue to explore the build-out of a GMP facility near our old campus. Next, we have a few investor questions. What are the key areas of antibody research that you are able to conduct with your current capabilities at BioStrand? All right. Thanks, Julianne. There are several areas of antibody research already applied with our LENSai software. As outlined in the slide that should be before you here in blue, including analyses in the areas of target selection and validation, hit discovery, lead generation, and antibody developability. These offerings are things that we're using internally to continue to develop case studies and to enhance internal research, but also offerings that are available to our clients and partners as well. Our next question is, IPA had a very big loss this quarter and is down CAD 19 million in cash. Does IPA have enough cash to see PolyTope through phase I? Sure. I can touch on that one as well. While our spend was up this quarter, primarily due to the clinical manufacturing we previously mentioned, this was an anticipated cost. We actually came in slightly below our forecasted spend for Q1. We do feel that we have sufficient cash to see the PolyTope through phase I and phase IIA as originally planned. As we previously stated, we've had several partners express interest in seeing the initial safety profile in human phase I, and we built in additional cost and time parameters to enable a smooth and relatively quick transition to any potential sponsors. We thank you for submitting your thoughtful and concise questions today. We hope that they were answered either in our script, in the Q&A, or in the MDA. I will move us on to closing remarks with some insight into this current fiscal year strategic planning. Great. Thank you, Julianne. To wrap up this conference call, we'd like to thank, first of all, IPA's employees, directors, clients, partners, and of course, our shareholders for being a part of this exciting journey of acceleration and transformation with us. We believe that some of our more recent advancements have the potential to disrupt multiple industries going forward, including market sectors such as precision medicine, therapeutic antibody generation, vaccine discovery and development, antibody humanization, and the transgenic animal industry, and lastly, the market of biosimilars. Alone, the global monoclonal antibody market is expected to surpass approximately $524 billion by 2030, registering a growth at a CAGR of 12.8% from 2022 to 2030. Our aim is clearly to capture a meaningful market share by offering unparalleled technologies in a truly end-to-end fashion on an accelerated timeline, enhancing our already clinically validated wet lab capabilities with state-of-the-art in silico technologies. The surging prevalence of cancer and other chronic diseases is boosting the demand for biologics, and it's expected to foster the growth of the global monoclonal antibody market for the foreseeable future. Pharmaceutical company investments in genomics are rising, coupled with the emergence of technologically advanced genomic platforms such as multi-species next-generation sequencing, which is expected to significantly boost the antibody market in the upcoming years. Also, according to Precedence Research, monoclonal antibodies are widely accepted biologics that are expected to provide lucrative growth opportunities to the market players in the foreseeable future, driven in part by rising awareness regarding the benefits and effectiveness of monoclonal antibodies. Major specific areas of increasing investment by biopharmaceutical companies are in the areas of human monoclonal antibody research, multi-omic analysis, and research on the molecular basis of disease and growing next-generation applications of antibodies. We also note the projection of significant growth rates for humanized antibodies, more effective anti-cancer antibodies with higher safety profiles and lower off-target effects, alongside a rising awareness regarding monoclonal antibodies and their effectiveness in the treatment of cancer. We are pleased to have shared our streamlined focus on a few specific assets in Talem that have been deemed ready for out-licensing and look forward to the active process of partnering for them this fall. We share your enthusiasm as we currently sponsor the world's only still efficacious first generation anti-COVID antibody as it nears the clinic. As stated previously, we've avoided the pitfalls which some development programs have succumbed to. Regulatory submission is rapidly approaching, with drug product delivery to clinics expected in the end of October. With that said, we hope to see you all on the next call and thank you for joining us today. This concludes today's conference call. Thank you for your participation. You may now disconnect.